Lannett injects $50m into Wyoming generic opioid build

By Dani Bancroft

- Last updated on GMT

iStock/Danielrao
iStock/Danielrao

Related tags Active ingredient Opioid

Lannett Company, Inc. has announced it will invest $50m into its generic analgesic manufacturing subsidiary Cody Labs, creating 45 new jobs in the Wyoming facility.

Cody Laboratories, Inc. was bought by the Philadelphia-based active pharmaceutical ingredient (API) manufacturer Lannett in 2007.

The labs specialise in pharmaceutical manufacturing of generics​ including Hydrocodone and Hydromorphone, both common opioid-based drugs prescribed for pain management.

In addition to Cody Lab’s current 130 employees, the new $50m​ (€46.8m) expansion will create 45 new jobs in the town of Cody, Wyoming.

Construction is planned to begin this spring, to be completed by Q3 2018 and for commercial operations to start by end of 2020.

Lannett has previously shown significant investment​ into its manufacturing capabilities in the Mid-West of the US.

Arthur Bedrosian, CEO of Lannett, said “[the] plan to invest in our pain management facilities will significantly increase our active pharmaceutical ingredients (APIs) production and bolster our efforts to vertically integrate,” ​in an SEC filing.

Cody Labs and Lannett could not be reached for further comment.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars